PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.03
D/E of 0.03 while TRAW has all-equity financing. Bruce Berkowitz would demand higher returns to justify our leverage.
14.82
Much higher net debt at 1.25-1.5x TRAW's 11.31. Bill Ackman would demand clear deleveraging catalysts.
No Data
No Data available this quarter, please select a different quarter.
18.83
Current ratio exceeding 1.5x TRAW's 7.44. Charlie Munger would verify if this advantage translates to better supplier terms.
No Data
No Data available this quarter, please select a different quarter.